关键词：脊髓;创伤和损伤;异常;血清;出血;磁共振成像;创伤
摘 要：Preclinical work has demonstrated that glibenclamide administration improves outcomes in rat models of spinal cord injury, with the principal mechanism of action being amelioration of post-traumatic hemorrhagic necrosis (PHN). We hypothesize that some but not all patients with spinal cord injury, principally those with incomplete lesions, will respond to glibenclamide therapy. Our goal is identify early markers of injury that can be used to predict which patients may benefit from glibenclamide treatment. In this proposal, we will measure early biological markers of injury severity, specifically, serum biomarkers and T2 MRI findings obtained within hours of injury. We will subsequently correlate these early abnormalities with 6-month neurological examinations. During the first year of patient recruitment, we enrolled 6 patients. For the second year, the period 10/2011 through 10/2012, we enrolled 11 new patients. Five of the new patients have completed the entire 6 months study period. The remaining 6 patients are all scheduled for their 6 month final visit in January 2013.